People who have had a heart attack or who are at risk for a heart attack and who stopped taking aspirin alongside the P2Y12 inhibitor ticagrelor one month after undergoing percutaneous coronary intervention (PCI) saw a significantly reduced risk of clinically meaningful bleeding with no increased risk of clotting-related adverse events at 12 months compared with patients who continued taking aspirin and ticagrelor for a full year, in a study presented at the American College of Cardiology’s Annual Scientific Session.
Bernie Sanders bashes nonprofit hospitals over their tax breaks
WASHINGTON — Hospitals get tax breaks that are worth far more than the value of the charity care they provide in return for their tax-exempt
October 10, 2023